LiverFlo was designed, formulated, and manufactured with our steadfast commitment to uncompromising quality and exceptional results. LiverFlo is produced in ISO certified and cGMP certified facilities. We adhere to stringent specifications and place a premium on purified, pharmaceutical grade ingredients.
We offer a 100% satisfaction guarantee. If for whatever reason you are not satisfied with the quality of our product(s), please return it for a full refund or a
replacement product.
References:Gundermann K-J, A. Kuenker A, Kuntz E, Drozdzik M: Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol. Rep. 2011; 63: 643-659
Kuntz E, Kuntz H-D: Hepatology - Textbook and Atlas. 3rd edition. Chapter 40. Springer press
Gundermann K-J, Kuntz E: Therapy of alcohol and drug-induced liver disease by plant-derived drugs. Progress in Hepato-Gastroenterol. 1999; IV: 49-58
Javed S, Kohli K, Ali M: Reassessing bioavailability of silymarin. Altern. Med. Rev. 2011; 16: 239-249
Udapurkar P, Bhusnure O, Kamble S, Biyani K: Phyto-phospholipid complex vesicles and herbal drugs: a promising drug delivery system. IJHM 2016; 4: 14-20
McMillan JM, Walle UK, Walle T: S-adenosyl-L-methionine: transcellular transport and uptake by Caco-2 cells and hepatocytes. J. Pharm. Pharmacol. 2005; 57: 599-605
Testino G, Leone S, Ansaldi F, Borro P: Silymarin and S-adenosyl-L-methionine (SAMe): two promising pharmacological agents in case of chronic alcoholic hepatopathy. A review and a point of view. Minerva Gastroenterol. Dietol. 2013; 59: 341-356
Rasool M, Iqbal J, Malik A, Ramzan HS, et al: Hepatoprotective effects of Silybum marianum (Silymarin) and Glycyrrhiza glabra (Glycyrrhizin) in combination: a possible synergy. Evid. Based Complement. Alternat. Med. 2014;2014:641597. doi: 10.1155/2014/641597
Archakov AI, Selzovskyi AP, Lisov VI, Tsyganov DI, et al: Phosphogliv: mechanisms of therapeutic action and clinical efficiency. Vopr. Med. Khimii 2002; 48: 139-151
Lieber CS, Leo MA, Cao Q, Mak KM, et al: The combination of S-adenosylmethionine and Dilinoleoylphosphatidylcholine attenuates non-alcoholic steatohepatitis produced in rats by a high fat diet. Nutr. Res. 2007; 27: 565-573
Cao Q, Mak KM, Lieber CS: DLPC and SAMe combined prevent leptin-stimulated TIMP-1 production in LX-2 human hepatic stellate cells by inhibiting H202-mediated signal transduction. Liver International 2006; 26: 221-231
Cao Q, Mak KM, Lieber CS: DLPC and SAMe prevented a1(I)-collagen mRNA up-regulation in human hepatic stellate cells, whether caused by leptin or menadione. Biochem. Biophys. Res. Commun. 2006; 350:50-55
Iakimchuk GN, Gendrikson LN: Study of clinical efficiency of essential phospholipids and silymarin combination in nonalcoholic and alcoholic steatohepatitis. Eksp. Klin. Gastroenterol. 2011; #7: 64-69
Gundermann K-J, Kuntz E: Therapy of alcohol and drug-induced liver disease by plant-derived drugs. Progress in Hepato-Pharmacol. 1999; 4: 49-58
Skakun NP, Stepanova NY: Efficacy of Legalon and Essentiale in "TCN" induced liver damage. Antibiot. Med. Biotekhnol. 1986; 31: 781-784
Leiber CS: S-Adenosyl-L-methionine: its role in the treatment of liver disorders - Am J Clin Nutr 2002;76(suppl):1183S-7S.
Anstee QM. et.al.: S-adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility Journal of Hepatology 2012 vol. 57 j 1097-1109
Alier R Et al. Eur Rev Med Pharmacol Sci 2015; 19(16):3118-24
Basarongulu M et al. Wold J astroenterol 2013;19(8):1166-72
Tappy L. Le KA. Clin Res Hepatol Gastroentoerol 2012;36(6):554-60
Blaising J et al. Cell Microbiol 2013;15(11):1866-82
Machado RM et. al. J Nutr 2010;140(6):2525-31